News
Scientists identify new predisposing genes and microRNAS involved in hereditary cancer
Dr. Gabriel Capellá presents the hereditary cáncer-related projects of IDIBELL at the XI AECC Symposium
IDIBELL and CMRB launch a new Catalan Regenerative Medicine Program
The Center of Regenerative Medicine in Barcelona (CMR[B]) – currently located within the Barcelona Biomedical Research Park (PRBB) – and the Bellvitge Biomedical Research Institute (IDIBELL) have joined efforts to create the new Regenerative Medicine Program of Catalonia (P-CMR[C]).
Starvation causes atypical cell death
Researchers from the Cell death group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Cristina Muñoz-Pinedo, have characterized the cell death process due to starvation, in which the endoplasmic reticulum plays a leading role. Their work, chosen as the cover of the latest Molecular and Cellular Biology journal, was carried out within TRAIN-ERs, […]
IDIBELL and ICO researchers take part in RCD Espanyol’s Heath Day
April 29th, at 6pm Health Day blood donation campaign free invitation for RCDE – Valencia Mejor sin Cáncer Public Health Agency, the Blood and Tissue Bank, the Red Cross, the Spanish Association against Cancer, IDIBELL, the Spanish Society of Pharmacists and Farmapericos, the Catalan Federation of Adapted Sports and Afrucat
Chemoresistance in breast cancer is associated with the modulation of tumor cell populations
Researchers from the transformation and metastasis group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Eva González-Suárez, have been able to recreate and characterize the process of acquisition of resistance to chemotherapy in orthotopic animal models of breast cancer, unveiling the possibility of reversing this resistance after a period of rest from the […]
Researchers describe a new pathophysiological process of megalencephalic leukoencephalopathy (MLC) in astrocytes
Depolarization causes the formation of a ternary complex between GlialCAM, MLC1 and ClC-2 in astrocytes: implications in megalencephalic leukoencephalopathy.
IDIBELL researchers look for new drugs against melanoma
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) participated in a study published recently in the by the journal Investigative Dermatology, entitled “AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK / ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact […]
Bellvitge research receives 1 million euros in PERIS 2016-2020 funding
The Department of Health has issued the final resolution of the first call for research grants linked to the Strategic Plan for Research and Innovation in Health (PERIS) 2016-2020. Researchers from the University Hospital of Bellvitge (HUB), the Catalan Institute of Oncology (ICO) and the University of Barcelona (UB) and their research projects, managed through […]
An epigenetic lesion could be responsible for acute T-cell leukemia
Researchers from the Epigenetics and Cancer Biology Program (PEBC) led by Dr. Manel Esteller at the Bellvitge Biomedical Research Institute (IDIBELL) have discovered how an epigenetic lesion can lead to T-cell acute lymphoblastic leukemia. The article, published in the journal Leukemia, leader in the field of hematology, correlates the lesion with the activation of a […]